Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEO-BLADE: neoadjuvant nintedanib with gemcitabine and cisplatin in muscle-invasive bladder cancer
ISRCTN56349930Phase 2Completed
- Sponsor
- Clatterbridge Cancer Centre
- Start
- May 2014
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in bladder cancer comparing Nintedanib + gemcitabine + cisplatin, Placebo + gemcitabine + cisplatin and Safety sub-study: nintedanib + split-dose cisplatin (3 arms). Primary endpoint: Pathological complete response. Started May 2014; status: completed.
02
Drugs
nintedanibgemcitabinecisplatin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ISRCTN56349930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN56349930.